… ProQR Appoints David M. Rodman, MD as Chief Development … the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it … of RNA approaches to treating disease.” said Noreen R. Henig, MD, Chief Medical Officer. “There are very few …
… ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory … LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … codons,” said Daniel de Boer, chief executive officer of ProQR. "We welcome Dr. Yu to our scientific advisory board, …
… ProQR Announces Presentations on Programs in Ophthalmology at … LEIDEN, the Netherlands, July 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … II Presentation at OIS Retina Daniel de Boer, CEO of ProQR, will give a presentation highlighting the company’s …
… ProQR Announces Presentations at the European Oligonucleotide … and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Peter Adamson, PhD, SVP Ophthalmology Science of ProQR Presentation : Thursday, November 8 at 14:15 - …
… ProQR Announces Annual Meeting of Shareholders to be Held May … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … be made available in the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “Financials and …
Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022
Phase 2/3 Sirius and Celeste clinical trials of ultevur